WeightControl.com: What are the main findings?
Response: In this cohort study of 3389 patients with obesity, weight reduction at 1 year was associated with the medication’s active agent, its dosage, treatment indication, persistent medication coverage, and patient sex. Factors positively associated with achieving at least 10% weight reduction at year 1 included semaglutide (vs liraglutide), obesity as a treatment indication (vs type 2 diabetes), persistence with the medication, high dosage, and female sex.
WeightControl.com: What should readers take away from your report?
Response: Our findings provide timely data on longer-term weight outcomes in patients receiving treatment with injectable semaglutide or liraglutide for obesity or type 2 diabetes, as well as identify key characteristics that could inform the probability of achieving sustained weight loss of a magnitude large enough to provide clinically significant health benefits.
Many individuals may have high expectations to achieve substantial weight reductions with these medications. Our real-world findings suggest that this was not the case for most patients in our cohort, however, those who persisted with the medication experienced weight losses comparable to those shown in corresponding clinical trials.
WeightControl.com: What recommendations do you have for future research as a result of this work?
Response: Our study underlines the current challenges with treating type 2 diabetes and obesity with these highly effective medications, as only 4 in 10 patients in our cohort had persistent medication coverage at 1 year. These data suggest that future research should focus on identifying the reasons for discontinuation of medication use and interventions aimed at improving long-term persistence with these medications.
Disclosures: Dr Gasoyan reported receiving grant funding from the National Cancer Institute outside the submitted work. Dr Butsch reported advisory board fees from Novo Nordisk A/S and research funding from Eli Lilly and Co during the conduct of the study. Dr Rothberg reported receiving personal fees from the Blue Cross Blue Shield Association outside the submitted work. The other authors declared no conflict of interest.
Citation:
The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on September 14, 2024 by weightcontrol